Scrip
Addex's GORD candidate positive in Phase II
18 November 2009
Katie McQue
Please Login to read the full article.
18 November 2009
Katie McQue
Addex Pharmaceuticals' investigational reflux-inhibitor ADX10059 has met the primary endpoint in a Phase IIb trial in gastro-oesophageal reflux disease (GORD).
"We saw the number of symptom-free days increase by five-fold, an exciting and clinically meaningful effect for ADX10059 monotherapy,"...
Please Login to read the full article.
RELATED CONTENT
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
